CA3261000A1 - PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS - Google Patents
PYRIDO[4,3-D]PYRIMIDINES COMPOUNDSInfo
- Publication number
- CA3261000A1 CA3261000A1 CA3261000A CA3261000A CA3261000A1 CA 3261000 A1 CA3261000 A1 CA 3261000A1 CA 3261000 A CA3261000 A CA 3261000A CA 3261000 A CA3261000 A CA 3261000A CA 3261000 A1 CA3261000 A1 CA 3261000A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrido
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263358324P | 2022-07-05 | 2022-07-05 | |
| US63/358,324 | 2022-07-05 | ||
| US202263394338P | 2022-08-02 | 2022-08-02 | |
| US63/394,338 | 2022-08-02 | ||
| US202263414939P | 2022-10-11 | 2022-10-11 | |
| US63/414,939 | 2022-10-11 | ||
| US202363502931P | 2023-05-18 | 2023-05-18 | |
| US63/502,931 | 2023-05-18 | ||
| PCT/IB2023/056844 WO2024009191A1 (en) | 2022-07-05 | 2023-06-30 | Pyrido[4,3-d]pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3261000A1 true CA3261000A1 (en) | 2024-01-11 |
Family
ID=87426656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3261000A Pending CA3261000A1 (en) | 2022-07-05 | 2023-06-30 | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4551296A1 (https=) |
| JP (1) | JP2025525406A (https=) |
| KR (1) | KR20250029954A (https=) |
| CN (1) | CN119585286A (https=) |
| AU (1) | AU2023302139A1 (https=) |
| CA (1) | CA3261000A1 (https=) |
| CL (1) | CL2024003699A1 (https=) |
| CO (1) | CO2024016875A2 (https=) |
| CR (1) | CR20240556A (https=) |
| DO (1) | DOP2024000275A (https=) |
| IL (1) | IL317957A (https=) |
| MA (1) | MA71388A (https=) |
| MX (1) | MX2024015001A (https=) |
| PE (1) | PE20250259A1 (https=) |
| PY (1) | PY2352053A (https=) |
| TW (2) | TWI869913B (https=) |
| WO (1) | WO2024009191A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| TW202434606A (zh) * | 2022-11-17 | 2024-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合三環類化合物、其製備方法及其在醫藥上的應用 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| PE20252775A1 (es) * | 2023-04-05 | 2025-12-22 | Pfizer | Compuestos de pirido[4,3-d]pirimidina |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121194980A (zh) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药（上海）有限公司 | 三环类化合物及其用途 |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025130912A1 (zh) * | 2023-12-19 | 2025-06-26 | 正大天晴药业集团股份有限公司 | 三并环类化合物及其医药用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025228381A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugate and use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN119874616B (zh) * | 2025-03-28 | 2025-05-30 | 四川美域高生物医药科技有限公司 | 一种有机中间体及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| EP3541219B1 (en) | 2016-11-16 | 2024-01-24 | Wink Robotics | Eyelid covering and stabilization for automatic eyelash extension |
| EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| MY201312A (en) | 2017-06-02 | 2024-02-16 | Pfizer | Antibodies specific for flt3 and their uses |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| KR20220012255A (ko) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| WO2022199587A1 (zh) * | 2021-03-24 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| US20250034166A1 (en) * | 2021-09-27 | 2025-01-30 | Jacobio Pharmaceuticals Co., Ltd. | Polycyclic fused ring derivatives and use thereof |
-
2023
- 2023-06-30 AU AU2023302139A patent/AU2023302139A1/en active Pending
- 2023-06-30 IL IL317957A patent/IL317957A/en unknown
- 2023-06-30 CR CR20240556A patent/CR20240556A/es unknown
- 2023-06-30 WO PCT/IB2023/056844 patent/WO2024009191A1/en not_active Ceased
- 2023-06-30 CN CN202380051793.7A patent/CN119585286A/zh active Pending
- 2023-06-30 CA CA3261000A patent/CA3261000A1/en active Pending
- 2023-06-30 EP EP23744558.0A patent/EP4551296A1/en active Pending
- 2023-06-30 JP JP2024576355A patent/JP2025525406A/ja active Pending
- 2023-06-30 PE PE2024002870A patent/PE20250259A1/es unknown
- 2023-06-30 KR KR1020257003513A patent/KR20250029954A/ko active Pending
- 2023-06-30 MA MA71388A patent/MA71388A/fr unknown
- 2023-07-04 TW TW112124839A patent/TWI869913B/zh active
- 2023-07-04 TW TW113147938A patent/TW202513571A/zh unknown
- 2023-07-04 PY PY202302352053A patent/PY2352053A/es unknown
-
2024
- 2024-12-02 CL CL2024003699A patent/CL2024003699A1/es unknown
- 2024-12-03 MX MX2024015001A patent/MX2024015001A/es unknown
- 2024-12-09 CO CONC2024/0016875A patent/CO2024016875A2/es unknown
- 2024-12-30 DO DO2024000275A patent/DOP2024000275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024016875A2 (es) | 2024-12-19 |
| JP2025525406A (ja) | 2025-08-05 |
| PE20250259A1 (es) | 2025-01-29 |
| TW202409047A (zh) | 2024-03-01 |
| WO2024009191A1 (en) | 2024-01-11 |
| MA71388A (fr) | 2025-04-30 |
| PY2352053A (es) | 2025-03-06 |
| AU2023302139A1 (en) | 2024-12-19 |
| TWI869913B (zh) | 2025-01-11 |
| EP4551296A1 (en) | 2025-05-14 |
| IL317957A (en) | 2025-02-01 |
| TW202513571A (zh) | 2025-04-01 |
| MX2024015001A (es) | 2025-01-09 |
| CL2024003699A1 (es) | 2025-04-11 |
| DOP2024000275A (es) | 2025-01-31 |
| KR20250029954A (ko) | 2025-03-05 |
| CR20240556A (es) | 2025-01-29 |
| CN119585286A (zh) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3261000A1 (en) | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS | |
| IL308438A (en) | Pyrido[3,4-D]pyrimidine compounds inhibit mutant KRAS proteins | |
| EP3980010A4 (en) | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | |
| IL175813A0 (en) | PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | |
| HUE041382T2 (hu) | Pirrolo[2,3-d]pirimidin származékok janus-kináz inhibitorként | |
| EP2142544B8 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| EP3925669A4 (en) | 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE DERIVATIVE | |
| ZA200803173B (en) | Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors | |
| EP4267581A4 (en) | SUBSTITUTED IMIDAZO[1,5-B PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND THEIR USE | |
| CA3287880A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| EP4175957A4 (en) | 2,3-DISUBSTITUTED PYRIDO[3,4-B!PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | |
| EP4157845C0 (en) | Pyrrolo[2,3-d]pyrimidine derivatives | |
| HK40067927A (en) | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds | |
| PL4021452T3 (pl) | Podstawione związki (7h-pirolo[2,3-d]pirymidyn-4-ylo)aminowe przydatne jako inhibitory jak1 | |
| HK40076628A (en) | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | |
| CA3286684A1 (en) | Imidazo[1,2-a]pyrazine derivatives | |
| CA3287799A1 (en) | Imidazo[1,2-a]pyrazine derivatives | |
| HK40109573A (en) | Pyrido[4,3-d]pyrimidine compounds capable of inhibiting kras mutant proteins | |
| CA3270641A1 (en) | Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors | |
| HK40123927A (en) | Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors | |
| ZA202406459B (en) | Pyrido[1,2-a]pyrimidin-4-one derivatives | |
| HK40072354A (en) | 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives | |
| HK40061557A (en) | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia | |
| HK40117266A (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| HK40115318A (en) | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241231 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241231 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241231 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250404 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250514 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250605 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250612 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250612 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250616 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250801 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20260422 |